Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

被引：0
|
作者：
Åsa Ericsson
Adam Lundqvist
机构：
[1] Novo Nordisk Scandinavia AB,
[2] IHE,undefined
[3] The Swedish Institute for Health Economics,undefined
来源：
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词：
Liraglutide; Insulin Glargine; Basal Insulin; Insulin Aspart; Insulin Detemir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 248
页数：11
相关论文
共 50 条
  • [11] LIRAGLUTIDE-DEGLUDEC FIXED DOSE COMBINATION IMPROVES NASH/NAFLD IN PATIENTS WITH UNCONTROLLED TYPE II DIABETES MELLITUS
    Singh, K. P.
    Bindra, N.
    Prem, S.
    Chhabra, M.
    Rathi, V.
    Sharma, R.
    Rai, P. E.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 : A44 - A45
  • [12] Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
    Ran Wei
    Weihao Wang
    Xiusheng Huang
    Jingtao Qiao
    Jinghe Huang
    Chang Xing
    Qi Pan
    Lixin Guo
    Diabetology & Metabolic Syndrome, 15
  • [13] Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
    Wei, Ran
    Wang, Weihao
    Huang, Xiusheng
    Qiao, Jingtao
    Huang, Jinghe
    Xing, Chang
    Pan, Qi
    Guo, Lixin
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
  • [14] FIRST FIXED-RATIO COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES
    Rendell, M.
    DRUGS OF TODAY, 2015, 51 (03) : 185 - 196
  • [15] Efficacy and safety of a combination of insulin degludec and liraglutide (IDegLira) in patients with Type 2 diabetes after 1 year of treatment
    Gough, S. C. L.
    Woo, V. C.
    Rodbard, H. W.
    Linjawi, S.
    Poulsen, P.
    Korsholm, L.
    Bode, B. W.
    DIABETIC MEDICINE, 2015, 32 : 76 - 76
  • [16] Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence
    Mezquita Raya, Pedro
    Ampudia Blasco, Francisco Javier
    Hunt, Barnaby
    Martin, Virginia
    Larsen Thorsted, Brian
    Basse, Amaury
    Price, Hermione
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1349 - 1356
  • [17] An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
    Evans, Marc
    Billings, Liana K.
    Hakan-Bloch, Jonas
    Slothuus, Ulla
    Abrahamsen, Trine J.
    Andersen, Andreas
    Jansen, Jeroen P.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (04) : 340 - 347
  • [18] Fixed ratio combination insulin degludec/liraglutide (IDegLira) vs basal bolus therapy (insulin glargine-U100 plus insulin aspart) for the management of Type 2 diabetes: A short-term cost-effectiveness analysis in the UK setting
    Drummond, R.
    Malkin, S. J. P.
    Du Preez, M.
    Lee, X. Y.
    Hunt, B.
    DIABETIC MEDICINE, 2018, 35 : 198 - 199
  • [19] HDL LIPIDOMIC ANALYSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS RECEIVING FIXED-DOSE COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE
    Pappa, E.
    Vavli, E.
    Kostara, C.
    Bairaktari, E.
    Tsimihodimos, V.
    ATHEROSCLEROSIS, 2020, 315 : E65 - E65
  • [20] EFFECT OF THE FIXED-DOSE COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE ON SERUM LIPOPROTEIN METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Pappa, E.
    Arvaniti, E.
    Dimou, A.
    Kostara, C.
    Tellis, K.
    Tselepis, A.
    Bairaktari, E.
    Elisaf, M.
    Tsimihodimos, V.
    ATHEROSCLEROSIS, 2019, 287 : E127 - E128
12345